Abstract
Glucokinase is a key enzyme involved in regulating insulin secretion from the pancreatic ß-cell. The unique role of glucokinase in human glucose physiology is illustrated by the fact that genetic mutations in glucokinase can either cause hyperglycaemia or hypoglycaemia. Heterozygous inactivating mutations in glucokinase cause maturity-onset diabetes of the young (MODY), homozygous inactivating in glucokinase mutations result in permanent neonatal diabetes whereas heterozygous activating glucokinase mutations cause hyperinsulinaemic hypoglycaemia
Similar content being viewed by others
References
Middleton RJ. Hexokinases and glucokinases. Biochem Soc Trans. 1990;18(2):180–3.
Matschinsky FM, Magnuson MA, Zelent D, Jetton TL, Doliba N, Han Y, et al. The network of glucokinase-expressing cells in glucose homeostasis and the potential of glucokinase activators for diabetes therapy. Diabetes. 2006;55(1):1–12.
Postic C, Shiota M, Magnuson MA. Cell-specific roles of glucokinase in glucose homeostasis. Recent Prog Horm Res. 2001;56:195–217.
Matschinsky FM. Regulation of pancreatic beta-cell glucokinase: from basics to therapeutics. Diabetes. 2002;51 Suppl 3:S394–404.
Matschinsky FM, Glaser B, Magnuson MA. Pancreatic beta-cell glucokinase: closing the gap between theoretical concepts and experimental realities. Diabetes. 1998;47(3):307–15.
Iynedjian PB. Molecular physiology of mammalian glucokinase. Cell Mol Life Sci. 2009;66(1):27–42. Review.
Gloyn AL, Noordam K, Willemsen MA, Ellard S, Lam WW, Campbell IW, et al. Insights into the biochemical and genetic basis of glucokinase activation from naturally occurring hypoglycemia mutations. Diabetes. 2003;52(9):2433–40.
Grimsby J, Sarabu R, Corbett WL, Haynes NE, Bizzarro FT, Coffey JW, et al. Allosteric activators of glucokinase: potential role in diabetes therapy. Science. 2003;301:370–3.
Koranyi LI, Tanizawa Y, Welling CM, Rabin DU, Permutt MA. Human islet glucokinase gene. Isolation and sequence analysis of full-length cDNA. Diabetes. 1992;41(7):807–11.
Iynedjian PB, Möbius G, Seitz HJ, Wollheim CB, Renold AE. Tissue-specific expression of glucokinase: identification of the gene product in liver and pancreatic islets. Proc Natl Acad Sci U S A. 1986;83(7):1998–2001.
Liang Y, Jetton TL, Zimmerman EC, Najafi H, Matschinsky FM, Magnuson MA. Effects of alternate RNA splicing on glucokinase isoform activities in the pancreatic islet, liver, and pituitary. J Biol Chem. 1991;266(11):6999–7007.
Gasa R, Fabregat ME, Gomis R. The role of glucose and its metabolism in the regulation of glucokinase expression in isolated human pancreatic islets. Biochem Biophys Res Commun. 2000;268(2):491–5.
Iynedjian PB, Pilot PR, Nouspikel T, Milburn JL, Quaade C, Hughes S, et al. Differential expression and regulation of the glucokinase gene in liver and islets of Langerhans. Proc Natl Acad Sci U S A. 1989;86(20):7838–42.
Arden C, Harbottle A, Baltrusch S, Tiedge M, Agius L. Glucokinase is an integral component of the insulin granules in glucose-responsive insulin secretory cells and does not translocate during glucose stimulation. Diabetes. 2004;53(9):2346–52.
Iynedjian PB. Mammalian glucokinase and its gene. Biochem J. 1993;293:1–13.
Fernandez-Mejia C, Vega-Allende J, Rojas-Ochoa A, Rodriguez-Dorantes M, Romero-Navarro G, Matschinsky FM, et al. Cyclic adenosine 3', 5'-monophosphate increases pancreatic glucokinase activity and gene expression. Endocrinology. 2001;142(4):1448–52.
Grupe A, Hultgren B, Ryan A, Ma YH, Bauer M, Stewart TA. Transgenic knockouts reveal a critical requirement for pancreatic beta cell glucokinase in maintaining glucose homeostasis. Cell. 1995;83(1):69–78.
Postic C, Shiota M, Niswender KD, Jetton TL, Chen Y, Moates JM, et al. Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic ß cell-specific gene knock-outs using Cre recombinase. J Biol Chem. 1999;274:305–15.
Shiota M, Postic C, Fujimoto Y, Jetton TL, Dixon K, Pan D, et al. Glucokinase gene locus transgenic mice are resistant to the development of obesity-induced type 2 diabetes. Diabetes. 2001;50:622–9.
Glaser B, Kesavan P, Heyman M, Davis E, Cuesta A, Buchs A, et al. Familial hyperinsulinism caused by an activating glucokinase mutation. N Engl J Med. 1998;338(4):226–30.
Christesen HB, Jacobsen BB, Odili S, Buettger C, Cuesta-Munoz A, Hansen T, et al. The second activating glucokinase mutation (A456V): implications for glucose homeostasis and diabetes therapy. Diabetes. 2002;51(4):1240–6.
Dullaart RP, Hoogenberg K, Rouwe CW, Stulp BK. Family with autosomal dominant hyperinsulinism associated with A456V mutation in the glucokinase gene. J Intern Med. 2004;255(1):143–5.
Cuesta-Munoz AL, Huopio H, Otonkoski T, Gomez-Zumaquero JM, Nanto-Salonen K, Rahier J, et al. Severe Persistent Hyperinsulinemic Hypoglycemia due to a De Novo Glucokinase Mutation. Diabetes. 2004;53(8):2164–8.
Christesen HB, Tribble ND, Molven A, Siddiqui J, Sandal T, Brusgaard K, et al. Activating glucokinase (GCK) mutations as a cause of medically responsive congenital hyperinsulinism: prevalence in children and characterisation of a novel GCK mutation. Eur J Endocrinol. 2008;159(1):27–34.
Barbetti F, Cobo-Vuilleumier N, Dionisi-Vici C, Toni S, Ciampalini P, Massa O, et al. Opposite clinical phenotypes of glucokinase disease: description of a novel activating mutation and contiguous inactivating mutations in human glucokinase(GCK) Gene. Mol Endocrinol. 2009;23(12):1983–9.
Kassem S, Heyman M, Glaser B, Bhandari S, Motaghedi R, Maclaren NK, et al. Large islets, beta-cell proliferation, and a glucokinase mutation. N Engl J Med. 2010;362(14):1348–50.
Meissner T, Marquard J, Cobo-Vuilleumier N, Maringa M, Rodríguez-Bada P, García-Gimeno MA, et al. Diagnostic Difficulties in Glucokinase Hyperinsulinism. Horm Metab Res. 2008 Dec 3.
Sayed S, Langdon DR, Odili S, Chen P, Buettger C, Schiffman AB, et al. Extremes of clinical and enzymatic phenotypes in children with hyperinsulinism due to glucokinase activating mutations. Diabetes. 2009;58(6):1419–27.
Pal P, Miller BG. Activating mutations in the human glucokinase gene revealed by genetic selection. Biochemistry. 2009;48(5):814–6.
Wabitsch M, Lahr G, Van de Bunt M, Marchant C, Lindner M, von Puttkamer J, et al. Heterogeneity in disease severity in a family with a novel G68V GCK activating mutation causing persistent hyperinsulinaemic hypoglycaemia of infancy. Diabet Med. 2007;24(12):1393–9. Epub 2007 Nov 1.
Christesen HB, Brusgaard K, Beck Nielsen H, Brock Jacobsen B. Non-insulinoma persistent hyperinsulinaemic hypoglycaemia caused by an activating glucokinase mutation: Hypoglycaemia unawareness and attacks. Clin Endocrinol (Oxf). 2008;68(5):747–55.
Davis EA, Cuesta-Muñoz A, Raoul M, Buettger C, Sweet I, Moates M, et al. Mutants of glucokinase cause hypoglycaemia- and hyperglycaemia syndromes and their analysis illuminates fundamental quantitative concepts of glucose homeostasis. Diabetologia. 1999;42(10):1175–86.
Van de Bunt M, Edghill ML, Hussain K, Ellard S, Gloyn A. Gene duplications resulting in over expression of glucokinase are not a common cause of hypoglycaemia of infancy in humans. Mol Genet Metab. 2008;94(2):268–9.
Vaxillaire M, Samson C, Cavé H, Metz C, Froguel P, Polak M. Glucokinase gene mutations are not a common cause of permanent neonatal diabetes in France. Diabetologia. 2002;45(3):454–5.
Gloyn AL, Ellard S, Shield JP, Temple IK, Mackay DJ, Polak M, et al. Complete glucokinase deficiency is not a common cause of permanent neonatal diabetes. Diabetologia. 2002;45(2):290.
Njølstad PR, Søvik O, Cuesta-Muñoz A, Bjørkhaug L, Massa O, Barbetti F, et al. GI. Neonatal diabetes mellitus due to complete glucokinase deficiency. N Engl J Med. 2001;344(21):1588–92.
Njølstad PR, Sagen JV, Bjørkhaug L, Odili S, Shehadeh N, Bakry D, et al. Permanent neonatal diabetes caused by glucokinase deficiency: inborn error of the glucose-insulin signaling pathway. Diabetes. 2003;52(11):2854–60.
Porter JR, Shaw NJ, Barrett TG, Hattersley AT, Ellard S, Gloyn AL. Permanent neonatal diabetes in an Asian infant. J Pediatr. 2005;146(1):131–3.
Turkkahraman D, Bircan I, Tribble ND, Akcurin S, Ellard S, Gloyn AL. Permanent Neonatal diabetes mellitus caused by a novel homozygous (T168A) glucokinase (GCK) mutation: initial response to oral sulphonylurea therapy. J Pediatr. 2008;153(1):122–6.
Rubio-Cabezas O, Diaz GF, Aragones A, Argente J, Campos-Barros A. Permanent neonatal diabetes caused by a homozygous nonsense mutation in the glucokinase gene. Pediatr Diabetes. 2008;9(3 Pt 1):245–9.
Bennett K, James C, Mutair A, Al-Shaikh H, Sinani A, Hussain K. Four novel cases of permanent neonatal diabetes mellitus caused by homozygous mutations in the glucokinase gene. Pediatr Diabetes (in press)
Author information
Authors and Affiliations
Corresponding author
Additional information
The author has nothing to declare
Rights and permissions
About this article
Cite this article
Hussain, K. Mutations in pancreatic ß-cell Glucokinase as a cause of hyperinsulinaemic hypoglycaemia and neonatal diabetes mellitus. Rev Endocr Metab Disord 11, 179–183 (2010). https://doi.org/10.1007/s11154-010-9147-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11154-010-9147-z